Reports on the response of the biopharmaceutical industry to the problem of cardiovascular disease (CVD) in the United States. CVD as leading cause of premature death; Response to growing need for anticoagulant and antiplatelet drugs; Market for more effective drugs; Developing therapies.
Processing Request
No Comments.